ADMINISTERED VIA NASAL SPRAY AND IS EFFECTIVE WITHIN HOURS
Esketamine was approved by the FDA in 2019 to treat depression that has not responded to other therapies.
Unlike oral antidepressants, which often take four to six weeks to take effect, esketamine is administered via nasal spray and is effective within hours.
It is estimated that 5 million people in the United States have a depressive disorder that hasn’t resolved with current treatments. Esketamine may help those with treatment-resistant depression experience much-needed relief.